Program Penanggulangan Tuberkulosis Paru: Studi Naratif

Abdullah Azam Mustajab; Cuk Husni Kuswanto; Marwiati Marwiati

doi:10.37287/jppp.v5i1.1359

Abdullah Azam Mustajab Universitas Sains Al-Qur’an
Cuk Husni Kuswanto Puskesmas Ngadirejo Temanggung
Marwiati Marwiati Universitas Sains Al-Qur’an

DOI: https://doi.org/10.37287/jppp.v5i1.1359

Keywords: penanggulangan TB, tes cepat molekuler, tuberkulosis, TB resisten obat

Abstract

Tuberkulosis menjadi darurat kesehatan masyarakat diseluruh dunia karena menjadi penyebab utama kematian pada orang dewasa. Permasalahan tuberkulosis semakin berkembang mulai tuberkulosis laten, tuberkulosis aktif sampai dengan tuberkulosis yang resisten obat. Kondisi tersebut perlu mendapatkan perhatian dari meningkatkan temuan kasus TB karena temuan kasus masih rendah dan pengobatan yang cepat dan tepat. Tujuan penelitian ini yaitu peneliti menyajikan narasi pengalaman partisipan sebagai programmer TB. Metode penelitian studi kualitatif dengan pendekatan studi naratif tipe wawancara naratif. Partisipan penelitian sejumlah satu partisipan yang merupakan programmer TB yang sudah berpengalaman selama 22 tahun dan dilakukan triangulasi. Hasil penelitian mendapatkan beberapa tema yaitu upaya pencegahan, strategi meningkatkan cakupan target penemuan penderita TB paru, tatalaksana setelah diketahui TB positif, dan pengobatan TB resisten obat.

References

Aditama, W., Zulfikar, & Baning, R. (2013). Evaluasi Program Penanggulangan Tuberkulosis Paru di Kabupaten Boyolali. Journal Kesehatan Masyarakat Nasional, 7(6), 243–250.

Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J. W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., Benedetti, A., Bisson, G. P., Boeree, M. J., Bonnet, M., Brode, S. K., Brust, J. C. M., Cai, Y., Caumes, E., Cegielski, J. P., … Menzies, D. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet, 392(10150), 821–834. https://doi.org/10.1016/S0140-6736(18)31644-1

Assjari, & Permanarian, S. (2010). Desain penelitian naratif. JASSI_Anakku, 9(2), 172–183.

Behr, M. A., Edelstein, P. H., & Ramakrishnan, L. (2018). Revisiting the timetable of tuberculosis. The BMJ, 362(August), 1–10. https://doi.org/10.1136/bmj.k2738

Comas, I., Coscolla, M., Luo, T., Borrell, S., Holt, K. E., Parkhill, J., Malla, B., Berg, S., & Thwaites, G. (2014). Out-of-Africa migration and Neolithic co-expansion of Mycobacterium tuberculosis with modern humans. Nature Genetics, 45(10), 1176–1182. https://doi.org/10.1038/ng.2744.Out-of-Africa

Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., McHugh, T. D., Wills, G. H., Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., & Spigelman, M. (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 382(10), 893–902. https://doi.org/10.1056/nejmoa1901814

Creswell, J. W. (2008). Narrative research designs dalam Educational Research (3rd ed.). Pearson Education Intnc.

Furin, J., Cox, H., & Pai, M. (2019). Tuberculosis. The Lancet, 393(10181), 1–15. https://doi.org/10.1016/S0140-6736(19)30308-3

Gandhi, N. R., Andrews, J. R., Brust, J. C. M., Montreuil, R., Weissman, D., Heo, M., Moll, A. P., Friedland, G. H., & Shah, N. S. (2012). Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. International Journal of Tuberculosis and Lung Disease, 16(1), 90–97. https://doi.org/10.5588/ijtld.11.0153

Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006). Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 368(9547), 1575–1580. https://doi.org/10.1016/S0140-6736(06)69573-1

Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. J. (2014). Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. New England Journal of Medicine, 371(17), 1577–1587. https://doi.org/10.1056/nejmoa1407426

Houben, R. M. G. J., & Dodd, P. J. (2016). The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Medicine, 13(10), 1–13. https://doi.org/10.1371/journal.pmed.1002152

Kemenkes RI. (2015a). Petunjuk Teknis Pemeriksaan Tuberkulosis Menggunakan Alat Genexpert (pp. 1–12). Bhakti Husada.

Kemenkes RI. (2015b). Tuberkulosis, temukan obati sampai tuntas (pp. 1–7). Pusdatin.

Kemenkes RI. (2016). Permenkes RI Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. In Dinas Kesehatan.

Kemenkes RI. (2018). Tuberkulosis. In Tuberkulosis (p. 8). Pusat data dan informasi Kementrian Kesehatan RI. www.kemenkes.go.id

Kemenkes RI. (2019a). Apa itu TOSS TBC dan kenali gejala TBC. Promkes.Kemkes.Go.Id. https://promkes.kemkes.go.id/apa-itu-toss-tbc-dan-kenali-gejala-tbc

Kemenkes RI. (2019b). Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis. In Kementrian Kesehatan RI.

Kementrian Kesehatan RI. (2019). Penanggulangan TB Resisten Obat di Indonesia. Mediakom Kemenkes RI. https://mediakom.kemkes.go.id/2019/04/penanggulangan-tb-resisten-obat-di-indonesia/

Law, S., Piatek, A. S., Vincent, C., Oxlade, O., & Menzies, D. (2017). Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. The Lancet Public Health, 2(1), e47–e55. https://doi.org/10.1016/S2468-2667(16)30035-4

Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., Fréchet-Jachym, M., Robert, J., Veziris, N., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Schünemann, H. J., & Lienhardt, C. (2019). Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerging Infectious Diseases, 25(5), 936–943. https://doi.org/10.3201/eid2505.181823

Menteri kesehatan RI. (2019). Keputusan Menteri Kesehatan Republik Indonesia No HK.01.07/Menkes/755/2019 tentang pedoman nasional pelayanan kedokteran tata laksana tuberkulosis. http://depkes.go.id/downloads/Kepmenkes/FORNAS 011113.pdf

Merle, C. S., Fielding, K., Sow, O. B., Gninafon, M., Lo, M. B., Mthiyane, T., Odhiambo, J., Amukoye, E., Bah, B., Kassa, F., N’Diaye, A., Rustomjee, R., de Jong, B. C., Horton, J., Perronne, C., Sismanidis, C., Lapujade, O., Olliaro, P. L., & Lienhardt, C. (2014). A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis. New England Journal of Medicine, 371(17), 1588–1598. https://doi.org/10.1056/nejmoa1315817

Nathavitharana, R. R., & Fiedland, J. (2015). A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak. Eur Respir Journal, 46, 293–36.

Novanty, F., & Ningrum, D. N. (2016). Evaluasi Input Sistem Surveilens Penemuan Suspek Tuberkulosis (TB) di Puskesmas Wilayah Kerja Dins Kesehatan Kabupaten Magelang. Unnes Journal of Public Health, 5(2), 120–129.

O’Donnell, M. R., Padayatchi, N., Kvasnovsky, C., Werner, L., Master, I., & Horsburgh, C. R. (2013). Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection. Emerging Infectious Diseases, 19(3).

Olayanju, O., Limberis, J., Esmail, A., Oelofse, S., Gina, P., Pietersen, E., Fadul, M., Warren, R., & Dheda, K. (2018). Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. European Respiratory Journal, 51(5), 1–12. https://doi.org/10.1183/13993003.00544-2018

Schnippel, K., Ndjeka, N., Maartens, G., Meintjes, G., Master, I., Ismail, N., Hughes, J., Ferreira, H., Padanilam, X., Romero, R., te Riele, J., & Conradie, F. (2018). Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. The Lancet Respiratory Medicine, 6(9), 699–706. https://doi.org/10.1016/S2213-2600(18)30235-2

Schrager, L. K., Harris, R. C., & Vekemans, J. (2018). Research and development of new tuberculosis vaccines: A review. F1000Research, 7(0), 1732. https://doi.org/10.12688/f1000research.16521.2

Seshadri, C., Sedaghat, N., Campo, M., Peterson, G., Wells, R. D., Olson, G. S., Sherman, D. R., Stein, C. M., Mayanja-Kizza, H., Shojaie, A., Boom, W. H., & Hawn, T. R. (2017). Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection. PLoS ONE, 12(4), 1–15. https://doi.org/10.1371/journal.pone.0175844

Sofiyatun, V. (2019). Implementasi Program penanggulangan Tuberkulosis Paru. Higeia Journal of Public Health, 3(1), 74–86.

Vesga, J. F., Hallett, T. B., Reid, M. J. A., Sachdeva, K. S., Rao, R., Khaparde, S., Dave, P., Rade, K., Kamene, M., Omesa, E., Masini, E., Omale, N., Onyango, E., Owiti, P., Karanja, M., Kiplimo, R., Alexandru, S., Vilc, V., Crudu, V., … Arinaminpathy, N. (2019). Assessing tuberculosis control priorities in high-burden settings: a modelling approach. The Lancet Global Health, 7(5), e585–e595. https://doi.org/10.1016/S2214-109X(19)30037-3

WHO. (2013). Xpert MTB/Rif assay for the Diagnosis Pulmonary and Extrapulmonary TB in Adults and Children.

WHO. (2018). WHO Preferred Product Characteristics for New Tuberculosis Vaccines: Vol. Licence: C (V. and B. Department of Immunization (ed.)). World Health Organization. http://apps.who.int/iris/bitstream/handle/10665/273089/WHO-IVB-18.06-eng.pdf

WHO. (2019). WHO consolidated guidelines on drugresistant tuberculosis treatment. WHO.Int.